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Colony-stimulating factor (CSF)-1 controls the sur-
vival, proliferation, and differentiation of macro-
phages, which are recognized as scavengers and
agents of the innate and the acquired immune sys-
tems. Because of their plasticity, macrophages are
endowed with many other essential roles during
development and tissue homeostasis. We present
evidence that CSF-1 plays an important trophic role
in postnatal organ growth and kidney repair. Nota-
bly, the injection of CSF-1 postnatally enhanced kid-
ney weight and volume and was associated with
increased numbers of tissue macrophages. More-
over, CSF-1 promotes postnatal renal repair in mice
after ischemia-reperfusion injury by recruiting and
influencing macrophages toward a reparative state.
CSF-1 treatment rapidly accelerated renal repair
with tubular epithelial cell replacement, attenua-
tion of interstitial fibrosis, and functional recovery.
Analysis of macrophages from CSF-1-treated kid-
neys showed increased expression of insulin-like
growth factor-1 and anti-inflammatory genes that
are known CSF-1 targets. Taken together, these data
suggest that CSF-1 is important in kidney growth
and the promotion of endogenous repair and reso-lution of inflammatory injury. (Am J Pathol 2011, 179:
1243–1256; DOI: 10.1016/j.ajpath.2011.05.037)
Macrophages are versatile cells that have been long
recognized as immune effectors where their recruitment
to sites of injury is a fundamental feature of inflammation.
Although their role in host defense has been well docu-
mented, macrophages and their precursors are also impor-
tant during embryogenesis, normal tissue maintenance,
and postnatal organ repair.1,2 Almost all developing organs
contain a population of resident monocytes that infiltrate
very early during organogenesis and persist throughout
adult life.3–6 In addition to their phagocytic capabilities
during tissue remodeling-associated apoptosis,5,7 fetal
macrophages have many trophic effects that promote
tissue and organ growth.6,8,9
Colony-stimulating factor (CSF)-1 controls the differ-
entiation, proliferation, and survival of macrophages by
binding to a high-affinity cell-surface tyrosine kinase
receptor (CSF-1R), encoded by the c-fms proto-onco-
gene that is expressed on macrophages and their pro-
genitors.6 CSF-1 is critical for both adult and embry-
onic macrophage development. This is manifested by
multiple organ growth deficiencies observed in osteo-
petrotic (Csf1op/Csf1op) mice that have a spontaneous
mutation in the csf-1 gene. These mice show growth
restriction and developmental abnormalities of the
bones, brain, and reproductive and endocrine or-
gans,10–13 a phenotype that can be rescued by injec-
tion of exogenous CSF-1 or insertion of a csf-1 trans-
gene.14–16
In adult organs, there is considerable heterogeneity
of monocytes and macrophages with distinct subsets
defined by phenotype, function, and the differential
expression of cell surface markers.17–19 Subpopula-
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healing and tissue repair, supporting the concept that
some macrophage phenotypes can promote organ re-
generation after a pro-inflammatory state of injury.20
The concept of macrophage polarization states has
emerged; the M1 “classically activated” pro-inflamma-
tory cell type apparently opposed by an M2 “alterna-
tively activated” immune regulatory macrophage.18 In
general, these two states are thought to be analogous
to the opposing T helper 1 and T helper 2 immune
responses, although in both cases this model is prob-
ably too simplistic. Functionally, it is more likely that
distinct subpopulations of macrophages may exist in
the same tissue and play critical roles in both the injury
and recovery phases of inflammatory scarring.20
Our previous study provided evidence that the addi-
tion of CSF-1 to a developing murine kidney promotes a
growth and differentiation response that is accompanied
by increased numbers of macrophages.3 Furthermore,
with the use of expression profiling we demonstrated that
fetal kidney, lung, and brain macrophages share a char-
acteristic gene expression profile that includes the pro-
duction of factors important in the suppression of inflam-
mation and the promotion of proliferation.3 Embryonic
macrophages appear to play a positive trophic role that
may have parallel reparative functions in many adult tis-
sues undergoing repair and cellular replacement.1,20 A
number of studies have suggested that infiltrating macro-
phages along with the trophic factors they release partici-
pate in tissue repair of the kidney,20–22 brain,23 skin,24,25
lung,26 liver,27 heart,28 gastrointestinal tract,29,30 and skel-
etal muscle.31,32 Indeed, the pleiotrophic roles for CSF-1 in
reproduction, development of multiple organ systems, and
maternal-fetal interactions during pregnancy by macro-
phage-mediated processes have also been well de-
fined.2,33,34
To determine the physiological relevance of CSF-1
as a component of the mammalian growth regulatory
axis, CSF-1 was administered to neonatal mice. We
report that CSF-1 administration to newborn mice in-
creased body weight and kidney weight and volume
and was associated with increased numbers of mac-
rophages. Our results also establish that CSF-1 injec-
tion into mice after ischemia-reperfusion (IR) injury pro-
moted endogenous repair with characteristic rapid
re-epithelialization of the damaged tubular epithelium,
leading to functional recovery. Flow cytometric and
gene expression analyses were used to delineate the
macrophage profile present in the kidneys during the
early and resolution phase of IR injury with and without
CSF-1 therapy. We thus provide evidence that CSF-1
recruits macrophages to the reparative site and influ-
ences their phenotype, partly through an insulin-like
growth factor (IGF)-1 signaling response. Therefore,
macrophages under the stimulus of CSF-1 in an acute
setting of renal disease markedly accelerate renal cell
replacement and tissue remodeling while attenuating
downstream interstitial extracellular matrix accumul-
ation.Materials and Methods
Mice
Csf1r-enhanced green fluorescent protein (EGFP) trans-
genic or C57BL/6J mice were obtained from Monash
University Animal House, Melbourne, Australia. The csf1r-
EGFP transgenic mice express EGFP under the control of
the CSF-1R (c-fms) promoter and first intron.6 These mice
were backcrossed onto the C57BL/6J background for 10
generations. All experiments were approved by the Mo-
nash University Animal Ethics Committee, which adheres
to the Australian Code of Practice for the Care and Use of
Animals for Scientific Purposes.
Newborn Mouse Analysis
Newborn csf1r-EGFP transgenic mice received treatment
by i.p. injection at postnatal day (P) 0.5, P1.5, and P2.5.
Littermate newborn mice were injected with either mouse
recombinant CSF-1 protein (1 g/g of body weight; Chi-
ron Corporation, Emeryville, CA) or vehicle (PBS). Mice
were sacrificed at P30 for unbiased stereologic ap-
proaches to estimate kidney and glomerular volumes.
The kidneys from csf1r-null mutant mice10 and wild-type
kidneys were collected at P19, and the body and organ
weights were assessed.
CSF-1 and vehicle-injected littermate pups were sac-
rificed at P5 to investigate kidney macrophage number.
The number of csf1r-EGFP macrophages was quantified
from three sections at 1000 magnification, with a mini-
mum of three medullary and five cortical fields of view per
section.
Stereologic Estimation of Total Kidney and
Glomerular Volumes
Unbiased estimation was performed on the kidneys from
littermate mice injected with CSF-1 and vehicle at P30.
Kidneys were immersion fixed in 10% formalin for 48
hours and embedded in Technovit 7100 glycol methac-
rylate resin (Electron Microscopy Sciences, Hatfield, PA).
Tissue was then serial sectioned at 20 m, and every
10th and 11th sections were collected, beginning at a
random number, and stained with periodic acid-Schiff
reagent. To determine total kidney volume, every 10th
section was viewed on a RF3A microfiche reader (Fugi,
Tokyo, Japan) overlaid with a 2  2-cm grid at a final
magnification of 24.25. Total volume was calculated
with the Cavalieri Principle.35,36 Glomerular volume was
estimated with the physical dissector/fractionator princi-
ple as previously described37,38 where sections were
projected on an unbiased 2  2-cm grid at a final mag-
nification of 298.
Unilateral IR Injury in Adult Mice
Male mice (20 to 25 g) were anesthetized with 2% inhaled
isofluorane (Abbott Australasia Pty Ltd, Kurnell, Austra-
lia), and IR injury was induced by 40 minutes of left renal
artery clamping with a vascular clamp (0.4 to 1.0 mm;
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incision. After IR injury, mice either received mouse re-
combinant CSF-1 protein (Chiron Corporation) or vehicle
(PBS), starting at 3 days after the induction of injury and
continuing daily for 3 consecutive days. A third group of
mice served as a sham-operated control group in which
the animals were anesthetized, and a flank incision was
performed without renal artery clamping.
Functional Assessment
Csf1r-EGFP mice (20 to 25 g) were used for functional
assessment and placed in metabolic cages to obtain 24-
hour urine samples. Mice underwent bilateral IR injury for 25
minutes on both kidneys by flank incisions. After IR surgery,
mice were injected with CSF-1 (Chiron Corporation) or ve-
hicle (PBS) at 3, 4, and 5 days. Twenty-four–hour urinary
albumin excretion was measured with a murine-specific
albumin ELISA (Exocell Inc., Philadelphia, PA).
Histology and Immunofluorescence Microscopy
For structural analysis, csf1r-EGFP or C57BL/6J mice
were perfusion-fixed with 4% paraformaldehyde at 100
mmHg for 10 minutes. Mid-coronal kidney sections were
immersion fixed in 4% paraformaldehyde embedded in
paraffin wax and sectioned at 5 m and processed for
H&E staining for histopathologic analysis or deparaf-
finized and rehydrated for quantification of tubular epi-
thelial cell proliferation. For quantification of renal pathol-
ogy five fields of view per section at a magnification of
400 were assessed within the outer stripe of the outer
medulla (OSOM) of the kidney for proximal tubular dam-
age and protein cast formation in modification to a pre-
viously reported method.21 The percentage of renal dam-
age was graded on a scale of 0 to 4.0, with 0
representing normal tubules and no protein casts; 0.5,
minor tubular damage and protein cast formation; 1, in-
volvement of 10% of OSOM; 2, involvement of 25% of
OSOM; 2.5, involvement of 26% to 50% of OSOM; 3,
involvement of 51% to 75% of OSOM; and 4, widespread
damage 75% of OSOM.
For proliferating cell nuclear antigen (PCNA) quan-
tification, kidney sections were antigen retrieved in
boiling 10 mmol/L sodium citrate buffer, followed by
blocking nonspecific binding with the use of the MOM
blocking kit (Vector Laboratories, Burlingame, CA).
Sections were stained with mouse anti-PCNA primary
Ab (1:100; DakoCytomation, Glostrup, Denmark) for 30
minutes, followed by donkey anti-mouse Alexa Fluor 555
(1:1000; Molecular Probes, Eugene, OR) for 30 minutes.
PCNA-positive tubular epithelial cells were quantified in
five randomly selected fields of view per section at a
magnification of 400 within the OSOM.
For fluorescence visualization of csf1r-EGFP macro-
phages, after perfusion-fixation of adult and P5 kid-
neys, tissue was postfixed in 4% paraformaldehyde for
24 hours, transferred to PBS containing 30% sucrose
for overnight incubation at 4°C, embedded in OCT
(TissueTek, Tokyo, Japan), and stored at 80°C. Fro-
zen sections were cut at 5 m, washed in PBS, andblocked with 1% bovine serum albumin. For determi-
nation of collagen type IV localization, a goat anti-
human collagen type IV primary Ab (1:400; Southern
Biotech, Birmingham, AL) was added for 1 hour, fol-
lowed by a chicken anti-goat Alexa Fluor 488 (1:1000;
Molecular Probes) for 30 minutes. For macrophage
staining, sections were incubated with rat anti-mouse
F4/80 (1:100; AbD Serotec, Oxford, UK) for 1 hour, fol-
lowed by a goat anti-rat Alexa Flour 594 (1:1000; Molec-
ular Probes) for 30 minutes. After staining, sections were
counterstained with DAPI (1:10,000; Molecular Probes)
and then mounted with Fluorescent Mounting Medium
(DakoCytomation). Sections were analyzed with a Provis
AX70 fluorescent microscope (Olympus, Tokyo, Japan),
and fluorescent images were captured with the F-view II
digital camera (Soft Imaging System, Munster, Germany).
Hydroxyproline and SDS-PAGE Analyses of
Kidney Collagen Content
Hydroxyproline content was measured from one-half of
each kidney (cross-sectioning the same region of cortex,
medulla, and papilla for analysis) of sham control and
treated adult C57BL/6J mice (20 to 25 g) as previously
described.39,40 Hydroxyproline values were then multi-
plied by a factor of 6.94 to extrapolate collagen content
from each sample (because hydroxyproline represents
14.4% of the amino acid composition of collagen).41
Collagen concentration was then determined by dividing
collagen content as a percentage of the dry weight tis-
sue. The other half of each kidney was digested for the
detection of changes in interstitial collagen subtypes by
SDS-PAGE analysis.39,40 The pepsin-digested supernatant
fluids were then analyzed on 5% (w/v) acrylamide gels with
stacking gels of 3.5% (w/v) acrylamide. The 1(I) collagen
chains were separated from the 1(III) chains by interrupted
electrophoresis with delayed reduction of the disulfide
bonds of type III collagen. The gels were stained with 0.1%
Coomassie Blue R-250 overnight at 4°C and destained with
30% methanol supplemented with 7% acetic acid.42 Den-
sitometry of the 1(I) and 2(I) chains (representing type I
collagen monomers) was then performed with a calibrated
imaging densitometer and Quantity-One software version
4.1 (Bio-Rad, Hercules, CA).
Flow Cytometry of the CSF-1 Inflammatory
Profile
The left kidneys of neonatal csf1r-EGFP mice at P5 and
adult C57BL/6J mice (20 to 25 g) were removed and
prepared for single-cell suspensions. Kidneys were
placed in cold fluorescent-activated cell sorting (FACS)
buffer containing PBS supplemented with 0.2% bovine
serum albumin, 0.5 mol/L EDTA, and 0.02% NaAz. Kid-
neys were finely minced and incubated in HBSS contain-
ing 1 mg/mL Collagenase/Dispase (Roche Diagnostics,
Indianapolis, IN), 0.1% DNase I (Roche Diagnostics), and
5 mmol/L CaCl2 at 37°C for 30 minutes on a rotating
board. Cells were manually digested into a single-cell
suspension with a 1000-L pipette and further incubated
1246 Alikhan et al
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buffer and recovered by centrifugation at 400 g for 5
minutes at 4°C. Cells were filtered through a 40-m cell
strainer (BD Biosciences, North Ryde, Australia),
washed, centrifuged, and lysed with red blood cell lysis
buffer (8.3 g/L ammonium chloride, pH 7.5). Cells were
adjusted to 3  106 cells/test in 96-well trays and stained
with the following mAb cocktail for 15 minutes at 4°C:
CD45-APC Cy7 (clone 30-F11), CD11c-Pacific Blue,
(clone N418), mannose receptor (MR) CD206-Alexa Fluor
488 (clone MR5D3; BioLegend, San Diego, CA);
CD11b-PE Cy7 (clone M1/70) MHCII/1-A/1-E-PE (Clone
M5/114.15.2; BD Biosciences); and F4/80-APC (clone
BM8; eBioscence, San Diego, CA). For intracellular MR
staining, surface-labeled cells were fixed, permeabilized,
and stained for 30 minutes at 4°C with the use of the
CytoFix/CytoPerm kit (BD Biosciences) according to the
manufacturer’s instructions. Cells were washed twice in
1 Perm/Wash buffer (BD Biosciences) and finally resus-
pended in FACS buffer. Labeled kidney cells were then
analyzed with the FACSCanto II (BD Biosciences), and
flow cytometric data were analyzed with FlowJo software
version 8.8.6 (TreeStar, Palo Alto, CA).
Real-Time Quantitative PCR Gene Expression
Analysis
Total RNA was extracted from whole kidneys with the use
of the RNeasy Mini Kit (Qiagen, Doncaster, Australia),
and kidney macrophages were sorted on the expression
of CD45-APC (Clone 30-F11; BD Biosciences) and
CD11b-FITC (Clone M1/70; BD Biosciences) and the ab-
sence of CD11c-PE (Clone HL3; BD Biosciences) with
the use of the RNAqueous-Micro Kit (Ambion, Austin, TX)
according to the manufacturer’s instructions. RNA sam-
ples were reverse transcribed into cDNA with the use of
the High Capacity cDNA Reverse Transcription Kit (Ap-
plied Biosystems, Foster City, CA). Real-time quantitative
PCR (qPCR) of target mRNA expression was performed
with the TaqMan Universal PCR Master Mix (Applied Bio-
systems) and the TaqMan Gene Expression Assays (Ap-
plied Biosystems). Reactions were measured on the 7500
Real Time PCR System (Applied Biosystems), and rela-
tive quantification PCR analysis was analyzed with the
SDS software version 1.3 (Applied Biosystems). The
threshold cycle (Ct) values were measured in triplicate and
normalized against the endogenous control -actin to de-
termine the Ct value. The Ct value of the different treat-
ment groups was standardized against the control group to
yield theCt for each gene. The relative quantification was
then calculated as 2Ct and graphed. The primers were
as follows: Actb, Mm00607939_s1;Ccl2, Mm00441242_m1;
Nos2, Mm00440485_m1; Tnf, Mm00443258_m1; Cxcl2,
Mm00436450_m1; Ccl17, Mm00516136_m1; Mrc1,
Mm00485148_m1; Msr2, Mm00472833_m1; Arg1,
Mm00475988; Igf1, Mm00439561_m1; Wnt7b,
Mm01301717_m1; Tgfb1, Mm01178820_m1; Acta2,
Mm01546133_m1; andMmp9, Mm00442991_m1. All prim-
ers were purchased from Applied Biosystems.Microarray and Data Analyses
Microarray experiments were undertaken with the use of
Illumina Mouse Ref8 V2 gene expression arrays (San
Diego, CA). RNA was extracted from sorted macrophage
cells as described above with the use of the RNeasy
Micro Kit (Qiagen). Two technical replicates were in-
cluded to determine whether the RNA extraction and
labeling procedure and the hybridization procedure were
reproducible. RNA quantity was measured with a Nano-
drop ND1000 spectrophotometer (Rockland, DE), quality
was determined with a Bioanalyzer 2100 (Agilent, Santa
Clara, CA), and an RNA integrity number threshold of 8
was used for all samples. The procedures for amplifying
RNA, labeling, hybridization, scanning, and data extraction
were performed exactly as outlined previously with the fol-
lowing exception: The quantity of total RNA used in the initial
amplification process was 150 ng and the in vitro transcrip-
tion reaction was incubated for 14 hours.43 All microarray
data have been submitted to the ArrayExpress database
(http://www.ebi.ac.uk/arrayexpress) under the accession
number E-MTAB-557. Data were normalized with the
Figure 1. CSF-1 administration to newborn mice increased body and kidney
weights and kidney volume, and in comparison csf1r knockout mice exhibit
decreased body and kidney weights. A: Mean body and kidney weights of
CSF-1 or vehicle control mice at P30, after injection at P0.5, P1.5, and P2.5
(n  8 per group). CSF-1-treated mice had a 19% increase in body weight
(P  0.02) and a 19% increase in kidney weight (P  0.04) compared with
vehicle-injected controls. B: Unbiased stereologic estimation of kidney and
glomerular volumes at P30 after littermates received either CSF-1 or vehicle
control (n  3 per group). Kidney volume was increased by 28% (P  0.04),
whereas no significant change in glomerular volume was observed. C: Csf1r
knockout mice had significantly decreased body and kidney weights com-
pared with wild-type animals (n 3 per group). Body weight was decreased
by 15% (P  0.0002) and kidney weight by 28% (P  0.048). Data were
analyzed with a Student’s t-test (unpaired, 2-tailed); *P  0.05, **P  0.005.
Data are mean  SEMs. KO, knockout; Veh, vehicle; WT, wild type.
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Samples were grouped on the basis of treatment regime,
and genes were filtered on detection score whereby
genes had to be detected in 75% of the samples in
each group. Welch’s t-test was applied to determine
genes that were significantly different (P 0.05) between
the two groups. The lists of differentially expressed genes
were then subjected to pathway analyses within the In-
genuity Pathway Analysis software version 8.8 (Ingenuity
Systems, Redwood City, CA).
Cell Culture in Vitro
Bone marrow–derived macrophages (BMMs) were iso-
lated and cultured with an established protocol.44 Cells
were initially grown for 24 hours in serum medium with
CSF-1 protein (100 ng/mL; Chiron Corporation). Once
BMMs were plated, medium was replaced with serum-
free medium, and cells were synchronized for 24 hours.
BMMs were stimulated with CSF-1 protein (100 ng/mL;
Chiron Corporation) in the presence of anti-IGF-1 mAb (3
g/mL; R&D Systems, Minneapolis, MN) for 72 hours in
serum-free medium. Cell proliferation was measured with
the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium) (MTS) assay,
CellTiter 96 Aqueous One Solution Cell Proliferation As-
say (Promega, Madison, WI) according to the manufac-
turer’s instructions.
Statistical Analysis
Statistic analysis was performed with GraphPad Prism
software version 5.0 (GraphPad Software Inc., San Di-
A B
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F480 - APC
% %
CortexE CortexF
MedMedulla
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Results
CSF-1 Treatment Increases Body Weight and
Kidney Weight
The murine kidney undergoes significant postnatal mat-
uration. CSF-1 increases in the circulation and tissues,
including kidney, liver, and lung, in the immediate post-
natal period. To determine whether the availability of
CSF-1 is limiting in this period and to investigate the
role(s) that CSF-1 may play in postnatal renal develop-
ment, CSF-1 was administered to newborn csf1r-EGFP
mice at P0.5, P1.5, and P2.5.45 CSF-1 treatment resulted
in a significant 19% increase in body weight at P30 (P 
0.02) compared with littermate vehicle-injected controls
(Figure 1A). At day 30, a significant increase in kidney
weight (P  0.04) of 19% was also observed (Figure 1A).
Conversely, mice lacking CSF-1 signaling experienced
retarded growth. The kidneys from csf1r-null mutant mice
were assessed at P19 because of the shortened lifespan
of the animals.10 Overall body weight was significantly
decreased in knockout compared with wild-type mice of
the same age (Figure 1C; 10.53  0.11 versus 8.94 
0.06 g; P  0.0002). Furthermore, csf1r knockout mice
had a significant decrease in kidney weight compared
with their wild-type counterparts (Figure 1C; 0.078 
0.004 versus 0.064  0.003 g; P  0.05).
Unbiased stereology was used to estimate kidney and
glomerular volumes in CSF-1-injected kidneys compared
with littermate control-injected mice to determine whether
D
0.31 %
H
with CSF-1. A–D: Flow cytometric analysis of whole kidneys indicates
P5. Representative histograms show an increase in CD45	CD11b	CD11c cells
termate vehicle-injected controls (A). C: Positive staining was confirmed with
icroscopy show csf1r-EGFP macrophage infiltration (arrows) in kidneys at P5
clei are stained with DAPI (blue). Lowmagnification (100) shows that kidneys
cortex, compared with vehicle controls (E). G: Csf1r-EGFP macrophages show
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nal volume or glomerular changes. At P30 the increase in
kidney weight in CSF-1-treated mice correlated with a
28% increase in total kidney volume compared with
littermate controls (Figure 1B). This increased volume
was not associated with glomerular hypertrophy with
no alteration in glomerular volume (Figure 1B). At P5,
flow cytometric analysis of kidney macrophages after
CSF-1 treatment showed an increase in both cell num-
ber (53.5  0.8 versus 67.5  2.2; P  0.003) and
proportion (34,633  3561 versus 46,750  2864; P 
0.04) of CD45	CD11b	CD11c cells expressing the
macrophage marker F4/80 (Figure 2, A–D). Semiquanti-
tative analysis of the number of interstitial csf1r-EGFP
cells showed significant increases in both the medulla
(157%; P  0.003) and cortex (42%; P  0.004; Figure 2,
E–H). Furthermore, the csf1r-EGFP cells displayed a
more elongated, spindle-like structure and were regularly
found to wrap around tubules (Figure 2G).
Structural Regeneration and Functional
Recovery in Response to CSF-1
On the basis of the observations of the role of CSF-1 in
growth and development of the kidney in newborn mice,
we tested the effect of CSF-1 in promoting kidney repair
after IR injury (see diagram in Figure 3A). IR injury of the
kidney leads to tubular epithelial cell damage within the
OSOM, the area most susceptible to hypoxic damage.
Compared with sham-operated kidneys, at 5 days after
IR injury widespread tubular epithelial cell damage was
evident with a prominent inflammatory cell infiltrate, inter-
stitial matrix expansion, and tubular cast formation (Fig-
ure 3B). By contrast, when mice with IR injury were ad-
ministered CSF-1, there was an acceleration of renal
repair and reduced tubular damage (Figure 3, B and C),
also characterized by increased tubular epithelial cell
proliferation as measured by quantification of PCNA im-
munostaining in proximal tubules (Figure 3D). At 7 days
after IR in mice with vehicle injection, renal damage was
evident with numerous proteinaceous casts present and
a marked inflammatory cell infiltrate associated with the
accumulation of extracellular matrix proteins and intersti-
tial matrix expansion (Figure 3B). Quantification of the
histopathologic analysis of kidneys from IR mice with and
without CSF-1 treatment showed that CSF-1 treatment
rescued tubular damage as confirmed by the reduction in
the number and size of tubular casts and restoration of
the tubular epithelial cell layer (Figure 3C) that was as-
sociated with reduced tubular epithelial cell proliferation
(Figure 3D).
This reparative effect of CSF-1 therapy in IR mice was
further supported by evidence of functional recovery and
the expression of Wnt7b in sorted macrophage popula-
tions. Urinary albumin excretion was measured in 24-hour
urine samples from 7-day bilateral IR mice (Figure 3E).
Baseline urinary albumin levels were determined in both
vehicle- and CSF-1-treated groups before IR surgery (Fig-
ure 3E). At 7 days after bilateral IR surgery urinary albumin
levels of vehicle-treated mice were twice that of baselinemeasurements (Figure 3E; 88.69  18.59 versus 229.46 
22.52 g/24 hours). However, 24-hour urinary albumin ex-
cretion of IR mice treated with CSF-1 was not different from
Figure 3. CSF-1 treatment, starting at 3 days after IR injury, accelerates endogenous
cellular repair and improves renal function in adult mice after IR injury.A: Schematic
diagram of the dosing regimen for CSF-1 therapy, beginning at 3 days after unilateral
(40 minutes) or bilateral (25 minutes) renal artery clamping. B: Representative
H&E-stained sections showing the histoarchitecture of theOSOM from sham control
(original magnification, 200), 3 days after unilateral IR kidney, 5 and 7 days after
unilateral IR kidneys with vehicle or CSF-1 injections (original magnification,400).
C: Semiquantitative analysis of kidney injury from kidneys 5 and 7 days after IR with
vehicle or CSF-1 treatment. Data were analyzed by a one-way analysis of variance
with an accompanying Tukey’s post hoc test for multiple comparisons; *P  0.05,
**P  0.01, and ***P  0.001. D: Tubular epithelial cell proliferation measured by
immunostaining with PCNA in kidneys 5 and 7 days after IR treated with CSF-1 or
vehicle injections. Data were analyzed with a Student’s t-test (unpaired, 2-tailed);
*P  0.05. E: Functional analysis measuring 24-hour urinary albumin excretion at
baseline and in kidneys 7 days after bilateral IR. Albumin data were analyzed with a
two-way analysis of variance; *P  0.05. F: qPCR analysis of Wnt7b expression in
sortedmacrophagepopulations at 5 and 7days after IR in kidneys treatedwithCSF-1
or vehicle injections. Data were analyzed with a Student’s t-test (unpaired, 2-tailed);
*P 0.03. Data are means SEMs (n 5 to 6 per group). RQ, relative quantifica-
tion; Veh, vehicle.baseline measurements and approximately one-half that of
CSF-1 Mediates Renal Macrophages 1249
AJP September 2011, Vol. 179, No. 3vehicle-injected controls (Figure 3E; 130.47 17.14 versus
229.46  22.52 g/24 hours; P  0.05).
Recently, it was shown that Wnt7b ligand production
from in sorted macrophage populations in mouse IR kid-
neys is critical for repair of the kidney tubule basal lamina
and the proliferation and migration of epithelial cells.46
With the use of qPCR, the expression of Wnt7b in sorted
kidney macrophages was investigated with and without
CSF-1 therapy after IR injury. A significant increase in
Wnt7b expression was found in sorted kidney macro-
phages (CD45	CD11b	CD11c) at day 7 after IR, a time
corresponding to both structural and functional recovery,
compared with vehicle-treated kidneys (Figure 3F; 1.091
 0.25 versus 3.25  0.75 relative quantification; P 
0.03).
Assessment of Collagen Accumulation
CSF-1 treatment of mice with IR injury reduced the accu-
mulation of interstitial collagen as assessed by hydroxy-
proline assay, SDS-PAGE analysis, and immunostaining
for type IV collagen. In IR kidneys a significant increase
was observed in total renal collagen concentration by
hydroxyproline assay at both 5 and 7 days, compared
with sham-operated kidneys (both P  0.01 versus sham
controls; Figure 4A). At 7 days after IR a significant de-
crease in total kidney collagen concentration (P  0.05)
was evident in CSF-1-treated mice than in kidneys fromvehicle-treated mice (Figure 4A). In addition, most of the
interstitial collagen in the kidney as assessed by SDS-
PAGE was type 1 collagen [1(I) and 2(I) monomers
and dimers of two 1(I) chains (11) or 1(I) and 2(I)
monomers (12)], with a smaller amount of type V colla-
gen also being present. At 7 days after IR, a significant
decrease was observed in collagen, particularly type 1
collagen, after CSF-1 treatment compared with vehicle-
injected IR mice as determined by scanning densitome-
try (Figure 4A). Furthermore, immunofluorescence mi-
croscopy was used to visualize type IV collagen
localization (Figure 4B). At 7 days, type IV collagen was
present as a fine framework within the glomerular and
tubulointerstitium without evidence of interstitial collagen
accumulation in IR kidneys after CSF-1 treatment, com-
pared with IR kidneys without treatment. These findings
suggest that CSF-1-dependent macrophages prevent fi-
brosis during tissue remodeling. At day 5, qPCR showed
a decreased expression of TGF- and -SMA in CSF-1-
treated animals compared with vehicle-injected IR mice,
with an up-regulation of MMP9 by day 7 (Figure 4C).
Alteration of Macrophage Phenotype after IR
Injury with CSF-1 Treatment
With the use of fluorescence microscopy at 7 days after
IR injury, a marked interstitial inflammatory response was
observed with an infiltration of csf1r-EGFP macrophages
Figure 4. CSF-1 reduces renal fibrosis by 7 days
after IR injury. A: Kidney collagen concentration,
SDS-PAGE analysis, and densitometry of sham,
and kidneys 5 and 7 days after IR treated with
CSF-1 or vehicle. Type I collagen monomers are
represented by 1(I) and 2(I) chains, 11 rep-
resents dimers of two 1(I) chains, whereas 12
represents dimers of 1(I) and 2(I) chains.
Type V collagen is represented by 1(V) and
2(V) chains. B: Representative fluorescent mi-
crographs showing type IV collagen (green) and
PCNA (red) staining at 7 days after IR injury with
and without CSF-1 treatment. Original magnifi-
cation, 400. Type IV collagen in the CSF-1-
treated IR kidneys displays a fine supportive net-
work around re-epithelialized tubules (arrows)
compared with interstitial collagen accumulation
(arrowheads) and disruption of the tissue ar-
chitecture evidence in vehicle-injected controls.
C: qPCR analysis of TGF-, -SMA, and MMP9
expression in sorted macrophage populations of
kidneys at 5 and 7 days after IR treated with
CSF-1 or vehicle injections. Hydroxyproline and
densitometry data were analyzed with a one-
way analysis of variance with an accompanying
Tukey’s post hoc test. qPCR analysis was ana-
lyzed with a Student’s t-test (unpaired, 2-tailed);
*P  0.05, **P  0.005, and ***P  0.0001. Data
are means  SEMs (n  5 to 6 per group). RQ,
relative quantification; Veh, vehicle.
ative im
1 injecti
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tubular casts. In response to CSF-1, csf1r-EGFP macro-
phages were also observed in large numbers in the tu-
bulointerstitium (Figure 5A), however, without evidence of
collagen accumulation or interstitial expansion. CSF-1-
responsive csf1r-EGFP macrophages manifested a spin-
dle-shaped structure such that the cells surrounded tu-
bules with interconnecting projections surrounding the
tubular basement membrane (Figure 5A).
Immunofluorescence staining was then used to deter-
mine the maturation status of the macrophage with the
use of the F4/80 antigen on csf1r-EGFP macrophages in
kidneys 5 and 7 days after IR with and without CSF-1
treatment. At 5 and 7 days (data not shown) after IR,
expression of F4/80 completely localized with csf1r-EGFP
in presumptive macrophages in the interstitium surround-
ing damaged tubules (Figure 5B). In CSF-1-treated kid-
neys, mature F4/80/csf1r-EGFP macrophages adopted a
flattened spindle-shaped structure that lined the base-
ment membrane of repaired tubules (Figure 5B).
Characterization of Macrophage Phenotype
after IR Injury in Response to CSF-1
The inflammatory profile and functional phenotype of
Figure 5. CSF-1 alters macrophage phenotype after IR injury. A: Representat
interstitial macrophages from sham control (original magnification, 200) an
400). In vehicle-injected IR kidneys there is a marked infiltrate of interstit
heads). In comparison, kidneys from the CSF-1-treated mice had a prominen
At high power the csf1r-EGFP macrophages in CSF-1-treated IR kidneys en
tubular basement membrane. Original magnification, 1000. B: Represent
csf1r-EGFP macrophages (green) 5 days after IR injury with vehicle or CSF-macrophages in response to CSF-1 was further exam-ined by flow cytometry, qPCR, and expression profiling
with the use of the Illumina Mouse Ref8 V2 gene ex-
pression arrays (Illumina) in C57BL/6J mice. At 5 days
after IR surgery, there was a large influx of macro-
phages (CD45	CD11b	CD11c), which increased
further in response to CSF-1, compared with vehicle-
(P  0.05) and sham-treated (P  0.001) kidneys (Fig-
ure 6A). The number of macrophages remained con-
sistent between 5 and 7 days after IR in vehicle-treated
animals, whereas the inflammatory infiltrate declined in
the CSF-1-treated animals, suggesting an accelerated
recovery (Figure 6A). These inflammatory cells pre-
dominantly expressed F4/80 and major histocompati-
bility complex (MHC) class II, and CSF-1 treatment did
not change the relative proportions of cells expressing
these markers (Figure 6A). However, CSF-1 adminis-
tration did increase the level of MHC class II expres-
sion on F4/80	 macrophages at 5 days after IR com-
pared with vehicle-treated animals, as shown by a
positive shift in the mean fluorescent intensity (P 
0.01; Figure 6B).
The accelerated resolution of the lesions in response
to CSF-1 suggested the presence of an anti-inflamma-
tory response. The macrophage MR has been associ-
ated with an anti-inflammatory phenotype in macro-
escent micrographs depicting the phenotypic changes of csf1r-EGFP (green)
ys 7 days after IR with and without CSF-1 treatment (original magnification,
ophages (arrows) with autofluorescent tubular casts also evident (arrow-
tial macrophage infiltrate that displayed a spindle-shaped structure (arrows).
he tubules with connecting cytoplasmic projections closely adjacent to the
munofluorescence microscopy showing co-expression of F4/80 (red) with
on. Original magnification, 400. L, tubular lumen.ive fluor
d kidne
ial macr
t intersti
velop tphages.47,48 The number of macrophages expressing
05, **P 
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cantly increased than with vehicle- (P  0.01) and
sham-treated (P  0.001) mice (Figure 6A). These MR
cells were also positive for F4/80 (Figure 6A) with a
shift from F4/80	MRhi population at 5 days after IR to a
F4/80	MRlo population at 7 days after IR in response to
CSF-1 (Figure 6C). In vehicle-treated mice, this phe-
notypic shift was mostly reversed with a F4/80	MRlo
population at 5 days after IR to a F4/80	MRhi popula-
tion at 7 days after IR injury (Figure 6C). These results
suggest that CSF-1 accelerates macrophage matura-
tion, leading to a more rapid resolution of injury.
The numbers of CD45	CD11b	CD11c macro-
phages in the inflamed kidney are sufficient to allow
detection of relevant macrophage-expressed genes
with the use of qPCR analysis. At 5 days after IR, CSF-1
therapy increased the initial inflammatory response, as
evidenced by TNF- and CCL2 expressions (Figure
Figure 6. CD45	CD11b	CD11c renal macrophages in CSF-1-treated mi
mice at 5 and 7 days after IR injury. Flow cytometric analysis was perfo
vehicle or CSF-1. A: Flow cytometric quantification of leukocytes stained
B: Representative histograms displaying the shift in mean fluorescent inten
C: Representative contour plots of F480 and MR co-expression on CD45	
isotype controls. Percentages of cells in each quadrant represent mean 
an accompanying Tukey’s post hoc test for multiple comparisons; *P  0.
mean fluorescent intensity; Veh, vehicle.7A) but did not alter iNOS and Cxcl2 expressions (Fig-ure 7A). By 7 days, these effects of CSF-1 were no
longer evident (Figure 7A). Conversely, at 5 days after
IR, CSF-1 therapy also induced the expression of ar-
ginase and CCL17 more often associated with an anti-
inflammatory phenotype, and by 7 days after IR mac-
rophage scavenger receptor 2 (MSR2) and MR were
also induced further by CSF-1 (Figure 7B).
Gene expression profiling was performed to further
examine the differentially expressed genes and altered
signaling pathways in sorted kidney macrophages at
both 5 and 7 days after IR injury with CSF-1 therapy
compared with untreated mice. Hierarchical clustering
of genes in each group showed distinct patterns of
gene expression because of time and treatment with
CSF-1. The largest difference in transcript expression
between vehicle and CSF-1 treatment samples was
seen at day 5 after IR; this was less obvious at day 7
after IR between treatment groups (Figure 8A). The
ay an altered phenotype and cell number compared with vehicle-treated
sham-operated kidneys and kidneys 5 and 7 days after IR treated with
0, MR, and MHC class II on CD45	CD11b	CD11c renal macrophages.
HC class II	 cells gated on CD45	CD11b	CD11c/F480	 macrophages.
CD11c macrophages. Positive staining was confirmed with appropriate
atistical analysis was performed with a one-way analysis of variance with
0.01, and ***P  0.001. Data are means  SEMs (n  5 per group). MFI,ce displ
rmed on
for F48
sity of M
CD11b	
SEM. Stlists of differentially expressed genes were then sub-
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use of Ingenuity Pathway Analysis software version 8.8
(Ingenuity Systems). Overrepresentation analyses are
a measure of probability that the gene lists at both 5
and 7 days after IR with CSF-1 treatment compared
with vehicle contains more members of the biochemi-
cal pathway than because of chance alone (Figure 8B).
Interestingly, in the day-5 CSF-1-treated macrophage
populations, the glucocorticoid receptor, IL-10, and
IGF-1 signaling pathways were identified, all are asso-
ciated with a M2 macrophage response (Figure 8B).
Networks of differentially expressed genes were also
generated with Ingenuity Pathway Analysis version 8.8
(Ingenuity Systems), and network hubs were identified
around IL-1 receptor antagonist, arginase, and mice
STAT3 molecules, all associated with an M2 macro-
phage response (see Supplemental Figures S1 and S2
at http://ajp.amjpathol.org). The pathways significantly
overrepresented in the day-7 CSF-1-treated macro-
phages included platelet-derived growth factor
(PDGF), granulocyte macrophage (GM)-CSF-1, and
apoptosis signaling (Figure 8B).IGF-1 Expression in IR Kidneys
IGF-1 has been shown to play an important role in the
reparative process of postischemic rat kidneys,49–51
and CSF-1 is known to control the expression of IGF-
1.52,53 We therefore investigated IGF-1 expression by
qPCR at 5 and 7 days after IR injury following CSF-1
therapy (Figure 9). In whole kidneys, at 5 days after IR
no difference in IGF-1 expression was observed be-
tween vehicle- and CSF-1-treated mice. However, by 7
days after IR, IGF-1 expression was significantly in-
creased in CSF-1 mice compared with vehicle-treated
animals (P  0.01; Figure 9A), which correlated with
the structural and functional recovery evident at the
same time point. To confirm that macrophages were
the source of IGF-1, we assessed the expression in
sorted CD45	CD11b	CD11c macrophage cells after
IR injury. IGF-1 was significantly up-regulated in CSF-
1-treated mice at both 5 (P  0.001) and 7 (P  0.01)
days after IR injury compared with vehicle-treated an-
imals (Figure 9A). In addition, BMMs cultured with
CSF-1 protein in the presence of IGF-1-neutralizing
Figure 7. qPCR analysis of pro-inflammatory
and anti-inflammatory gene expression in sorted
CD45	CD11b	CD11c macrophages from sham-
operated kidneys and kidneys 5 and 7 days after
IR treated with CSF-1 or vehicle injections. Pro-
inflammatory (INOS, TNF-, CCL2, and Cxcl2)
(A) and anti-inflammatory (CCL17, arginase,
MSR2, and MR) (B) gene expression in response
to CSF-1 treatment. Sham-operated kidneys were
used as the baseline control. Statistical analysis
was performed with a one-way analysis of vari-
ance with an accompanying Tukey’s post hoc
test for multiple comparisons; *P  0.05, **P 
0.01, and ***P  0.001. Data are means  SEMs
(n  5 per group). RQ, relative quantification;
Veh, vehicle.antibody inhibited CSF-1-stimulated BMM cell prolifer-
hat pass
inoid X
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growth by IGF-1 signaling (Figure 9B).
Discussion
The pleiotrophic role for CSF-1 in reproduction, including
mammary branching morphogenesis and placental
growth, suggest that CSF-1 exerts many of its actions
through the trophic activities of cells of the mononuclear
phagocytic lineage.54 Fetal macrophages are among the
first hematopoietic cells found in the kidney, entering
the murine kidney at embryonic day 12.3 Furthermore, the
Figure 8. Microarray analysis of sorted macrophage populations from kidn
expressed genes in each group, where blue represents low gene expres
significantly overrepresented in sorted macrophages from kidneys 5 and 7 d
indicates the cutoff probability (P  0.05) calculated from a right-tailed Fish
Systems). The ratio line indicates the number of genes from the gene list t
pathway. ATM, ataxia telangiectasia mutated; LXR/RXR, liver X receptor/retnumbers of macrophages in most major organs of themouse undergo a substantial numerical increase in re-
sponse to a postnatal surge of CSF-1.2,14 In the current
study, we report that CSF-1 increases overall body
weight and kidney weight and volume when administered
during the final week of development, and we provide
evidence that this is accompanied by an increase in
macrophage numbers in the kidneys with the use of a
csf1r-EGFP reporter mouse described previously.6
Osteopetrotic (csf1op/csf1op) mice that have a sponta-
neous mutation in the csf1 gene, show growth restriction
and developmental abnormalities11,12,23 that can be par-
tially reversed by the exogenous administration of
nd 7 days after IR with or without CSF-1 therapy. A: Hierarchical cluster of
d red represents high gene expression. B: Canonical signaling pathways
IR with CSF-1 therapy compared with vehicle treatment. The threshold line
t test within the Ingenuity Pathway Analysis software version 8.8 (Ingenuity
cutoff criteria in the pathway divided by the total number of genes in the
receptor; TRK, tyrosine kinase receptor; Veh, vehicle.eys 5 a
sion an
ays after
er’s exacCSF-1.16 Targeted disruption of the csf1r gene results in
for mul
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reproductive defects similar to csf1op/csf1op mice yet
more severely.10 Here, we further show that csf1r-null
mice have decreased kidney weight. The CSF-1-deficient
csf1op/csf1op mouse has many developmental deficien-
cies in common with the IGF-1-deficient mouse, including
a failure to produce insulin-producing cells in the islets,
neurologic defects, deficiencies in male and female re-
productive systems, and failure of mammary gland de-
velopment.55 Our previous report showing that CSF-1
can promote nephrogenesis in kidney explants3 is anal-
ogous to the growth-promoting role of IGF-1 in human
fetal kidney explants that supports the induction and dif-
ferentiation of the nephrogenic zone.56 The production of
IGF-1 by CSF-1-stimulated macrophages has been rec-
ognized previously,52,57,58 but no comparative abun-
dance data have previously been presented.
The present data suggest that macrophages respond
to CSF-1 signaling by the production of IGF-1, an essen-
tial growth factor that regulates postnatal growth and
development.55 In fact, the biology we observe is consis-
tent with a study of muscle regeneration, in which IGF-1
not only promotes repair but also dampens expression of
inflammatory cytokines.59 The other possibility is that
there is another cell type able to transduce the CSF-1
signal. Indeed, Menke et al60 have also reported that
CSF-1 can promote kidney repair but conclude that the
renal epithelium itself expresses the CSF-1R, suggesting
a direct signaling mechanism for this outcome. They re-
port the detection of CSF-1R mRNA and protein on
mouse primary tubular epithelial cells in vitro, although at
a very low level in comparison to macrophage lines.60
Local microenvironmental cues play an important role
in macrophage heterogeneity. Therefore, CSF-1 activa-
tion of tissue macrophages may influence the growth,
proliferation, and maturation of the kidney during organo-
genesis, a phenomenon that may be mirrored in repairing
kidneys after CSF-1 therapy. We report that the adminis-
tration of CSF-1 to mice with established IR injury resulted
in tubular epithelial proliferation, attenuation of interstitial
fibrosis, and functional recovery. In many settings regen-
Figure 9. CSF-1 can promote macrophage growth and cell proliferation by
macrophages 5 and 7 days after IR injury with and without CSF-1 treatment. B
of IGF-1 neutralizing antibody (3 g/mL). qPCR data were analyzed with a
a one-way analysis of variance with an accompanying Tukey’s post hoc test
 SEMs (n  5 per group). RQ, relative quantification; Veh, vehicle.eration of the kidney is macrophage dependent, evi-denced by the switch of macrophage phenotype from a
pro-inflammatory to an anti-inflammatory phenotype,21
which is followed by the production of angiogenic and
anti-inflammatory factors in addition to phagocytic tissue
remodeling.22,61 The precise phenotype of the macro-
phages seen in the repairing kidney in our study does not
strictly conform to the M1/M2 dichotomy, because we see
expression of genes associated with both extremes and
the profile changes with time. Mosser and Edwards48
have suggested a third macrophage classification, asso-
ciated with wound healing, that is distinct from the M2
category. In reality, the repairing kidney should be con-
sidered as a unique environment. Induction of genes
such as IGF-1, and the MSR62 are probably direct re-
sponses to CSF-1. The macrophage MR is also highly
expressed in CSF-1-stimulated BMMs (see data at http://
www.bioGPS.org) and in macrophages of the embryo.48
Urokinase plasminogen activator is another relevant
gene that is inducible by CSF-1.63 Previous reports im-
plicate urokinase plasminogen activator in the prevention
of fibrosis in kidney and other tissues.64,65 Other genes
expressed by macrophages that we observed may be in
response to the presence of apoptotic cells. Our microar-
ray profiling of differentially expressed genes and signal-
ing pathways showed distinct patterns that correspond to
macrophage phenotypes that showed genes in common
with csf1r-EGFP-expressing macrophages during embry-
onic development.3
Original studies of CSF-1 administration to adult mice
showed that it can increase circulating monocytes and
tissue macrophages.66 Notwithstanding the surge in
availability in the postnatal period, injected CSF-1 can
additionally promote postnatal growth in newborn mice.
We have recently reported that the administration of
CSF-1R blocking antibody selectively reduced monocyte
precursors of resident tissue macrophages.67 The cur-
rent study suggests that CSF-1 acts, at least in part,
through production of IGF-1 by kidney macrophages. We
further propose that an activation of CSF-1 by tissue
macrophages creates a microenvironment that influ-
ences the growth, proliferation, and differentiation of re-
ignaling. A: qPCR analysis of IGF-1 expression in adult kidneys and sorted
roliferation assay of BMMs cultured with CSF-1 (100 ng/mL) in the presence
’s t-test (unpaired, 2-tailed), and MTS proliferation data were analyzed with
tiple comparisons; *P  0.01, **P  0.01, and ***P  0.001. Data are meansIGF-1 s
: MTS p
Studentnal epithelial cells and promotes matrix remodeling and
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AJP September 2011, Vol. 179, No. 3cellular replacement in an inflammatory setting. CSF-1
thus may bias the macrophage response to one of me-
diating tissue repair rather than driving inflammation.
An understanding of the factors that control differenti-
ation and activation of regenerative macrophages and
the environmental cues that govern the outcome of
inflammation is vital to the successful development of
cellular-based therapies that may prevent or retard the
progression of renal disease.
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